Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study

Dengue disease and its causative agents, the dengue viruses (DENV-1–4), cause high morbidity in tropical and subtropical regions. We evaluated three dosing regimens of the investigational tetravalent AS03(B)-adjuvanted dengue-purified inactivated vaccine (DPIV+AS03(B)). In this phase 1/2, observer-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Leyi, Lyke, Kirsten E., Koren, Michael, Jarman, Richard G., Eckels, Kenneth H., Lepine, Edith, McArthur, Monica A., Currier, Jeffrey R., Friberg, Heather, Moris, Philippe, Keiser, Paul B., De La Barrera, Rafael, Vaughn, David W., Paris, Robert M., Thomas, Stephen J., Schmidt, Alexander C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356407/
https://www.ncbi.nlm.nih.gov/pubmed/32342848
http://dx.doi.org/10.4269/ajtmh.19-0738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356407/
https://www.ncbi.nlm.nih.gov/pubmed/32342848
http://dx.doi.org/10.4269/ajtmh.19-0738

Ejemplares similares